Search 

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick, NJ, with an Innovation Center in Cambridge, MA. The firm invests in a variety of fields within the life science sector, including medical devices. J&J’s medical device investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment. J&J is interested in early stage medical device companies located globally.

Joslin Diabetes Center is a foundation based in Boston, Massachusetts that was founded in 1898, and is the world's largest diabetes and clinical care organization.

JT Pharma, the Pharmaceutical Division of Japan Tobacco (Akros Pharma, US; Torii, Japan) has broad therapeutic interests with a focus on cutting edge, innovative science and orally active small molecule therapeutics in diabetes, lipid regulation, osteoporosis (small molecule anabolic agents), HIV, HBV, fibrosis, pain, autoimmune diseases, inflammation (RA and OA), urological diseases, allergy, and new drug discovery and development tools. Torii, the marketing division of JT Pharma Division, is interested in late stage, i.e. late Ph3, close to registration drugs for the Japanese market. Torii’s areas of interest are: renal diseases including CKD and complications from hemodialysis, dermatology, atopic dermatitis (preferably given orally), psoriasis, allergy, i.e. antigen-specific immunotherapy, asthma, and rhinitis. JT Pharma and Torii are looking for commercializable technologies or products for collaborative R&D deals or in- licensing deals. 
JT Pharma seeks partnering opportunities, i.e., research and/or development collaborations, contract research and licensing arrangements, to enhance its own internal R&D efforts. Also, Japan Tobacco’s marketing division, Torii Pharmaceuticals, seeks late-stage clinical opportunities for the Japanese Market.
JT Pharma has an interest in early-stage, novel small molecule therapeutics focusing on diabetes,lipid regulation, HIV, HBV, autoimmune disease, inflammation (RA, OA, asthma, allergy), fibrosis, osteoporosis, overactive bladder, and pain (non-CNS) as well as new drug discovery and development tools. Compounds must have composition of matter patents.

Torii Pharmaceuticals is seeking drugs in clinical trials for licensing and marketing in Japan with a focus on dermatology (eczema, atopic dermatitis, psoriasis, onychomycosis, ), allergy, and kidney diseases.

JT Pharma is dedicated to the discovery, development, and sales of novel human therapeutics. In addition to the North American facilities mentioned above, most of JT Pharma’s new drug discovery and development work is performed within its Central Pharmaceutical Research Institute, located in Osaka. They also have a molecular biology research laboratory in Yokohama and a toxicology research facility in Hadano, Japan.

Jump Capital was founded in 2012 and is based in Chicago, with an additional office in San Francisco. The firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, Jump Capital typically allocates $2-15 million, and prefers to invest in Series B-C rounds. Jump Capital invests in the USA and Canada, and has previously invested in 6 healthcare companies.

Jump Capital invests in medical devices, diagnostics, digital and mobile health, and healthcare services. The firm is open to opportunities in any clinical indication. Jump Capital is only interested in devices and diagnostics that have in-human data.

JVC Investment Partners is a private investment firm that was founded in 2000 and is based in Chicago, Illinois. The firm focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

Kairos Therapeutics has developed a proprietary next generation antibody-drug conjugate (ADC) platform based on novel toxin, linker and site-specific conjugation technology. Kairos has demonstrated superior pre-clinical in-vivo efficacy over T-DM1. Further pre-clinical studies demonstrate Kairos’ ADCs have superior tolerability and therapeutic index, compared to other leading platforms which may lead to greater clinical efficacy. Through key partnerships, Kairos is developing a novel therapeutic pipeline and is out-licensing its ADC platform to companies seeking access to state-of-the-art technology.  

Kineta® is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. Our company is focused on the development of novel drug candidates each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed NIH-supported research.

Life Science Angels Inc was founded in 2004 and is based in Sunnyvale CA. The group makes early-stage equity investments in a wide range of life science companies. Life Science Angels invests primarily in California but is open to investing out of state provided a round is being syndicated with a local angel group. Life Science Angels does not rule out investing outside the USA but has yet to do so. The group invests as individuals and allocation sizes are therefore highly varied but are usually of about $2-$6, Life Science Angels usually invests in rounds seeking $3 million or less. The group is interested in syndicating rounds with other angel groups.